Stada's owners are also mulling
bids for the generic drug business being sold by Sanofi, the sources said, and might favor this combination over Merck as generic drugs are typically valued at a cheaper multiple.
Here's how it went: Shortly before 9 a.m. New York time (and before U.S. markets opened),
generic drug giant Teva Pharmaceutical (TEVA) confirmed its unwelcome
bid to acquire rival Mylan (MYL)
for $ 40 billion.